This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

LORNE K. Direnfeld, MD, FRCP(C)
Maui Clinic Kahului, Hawaii

Ladislav Volicer, MD, PhD
Departments of Pharmacology and Medicine E. N. Rogers Memorial Veterans' Hospital Bedford, Mass

Philip J. Langlais, MA
Brain Tissue Resource Center McLean Hospital Belmont, Mass

Judith Marquis, PhD
Department of Pharmacology Boston University School of Medicine

Martin L. Albert, MD
Department of Neurology Veterans Administration Medical Center 150 S Huntington Ave Boston, MA 02130

Arch Neurol. 1985;42(12):1132-1133.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—We thank Drs Zetusky and Jankovic for their thoughtful comments, with which we are largely in agreement. Early in their letter they stated that "the population sample was small"; we certainly agree with that observation.

We welcome this opportunity to provide additional detail not included in the original report, as well as some corrections to minor misreadings by Drs Zetusky and Jankovic. Bradykinesia was given the most weight in our clinical assessment because it is often the single feature of Parkinson's disease that results in the greatest functional impairment.

We disagree with Drs Zetusky and Jankovic that the results of our study indicate that the PDL group had more severe bradykinesia, while the PDR group had more marked tremor. As shown in Table 1 of our article, there were no statistically significant differences in those features between the PDL and PDR groups. Nonetheless, the association of bradykinesia and intellectual impairment . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?